The goal of the HITLAB Women’s Health Tech Challenge is to fast-track support for innovative FemTech products that empower women to make informed choices about their health and improve women’s healthcare delivery. Individuals or teams who have identified a unique technology solution for a women’s health issue may apply for the Challenge through Sunday, May 3rd, 2020.

FemTech refers to software, diagnostics, products, and other technology-based services designed to improve women’s health. This rapidly growing market is projected to hit $50 billion by 2025. Health tech offerings that address reproductive wellness and pregnancy, gynecologic illnesses, and general health and wellness for women stand to do well in both the US and internationally over the next few years. FemTech health solutions can also pave the way for increased access to care for under-served women around the globe.

Five finalists in the Women’s Health Tech Challenge will have the opportunity to pitch to an international audience on Pitch Day, Thursday, May 21st. Due to the COVID-19 crisis, the 2020 event has gone virtual but that hasn’t stopped participants from around the world from registering for the event. General attendance at the virtual Pitch Day on May 21st includes opportunities to network with industry leaders and is open to anyone with an interest in FemTech health solutions.

An outstanding pitch could land finalists an investment of up to $20,000 from the Cavendish Impact Foundation. This organization accelerates impact in health and life science with a variety of programs that support disruptive entrepreneurship. A panel of judges will award a $6,000 grand prize along with in-service packages to the innovators who take 2nd through 4th place in the competition.

The rapid expansion of digital health already has investors keeping their eyes peeled for cutting-edge health tech solutions. The Women’s Health Tech Challenge sets the stage for creative innovators to secure a place for FemTech at the forefront of the digital health revolution.